Pivotal Evaluation of Abdominal Neuromuscular Electrical Stimulation (VentFree) for Weaning From Mechanical Ventilation
Launched by LIBERATE MEDICAL · Feb 24, 2023
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
Approximately 40% of patients who receive invasive ventilation require more than four days of ventilator support. Every additional day of mechanical ventilation results in increased patient morbidity and mortality and increased economic cost. Mechanically ventilated patients often develop expiratory muscle weakness, which has been linked to failed extubation and weaning.
Neuromuscular electrical stimulation (NMES) uses electrical pulses to induce a muscle contraction and has been shown to reduce or retard muscle atrophy. NMES applied to the abdominal wall muscles has been shown to improve ...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Participant is ≥ 22 years of age.
- • 2. Participant has been receiving invasive mechanical ventilation for ≥ 24 hours.
- Exclusion Criteria:
- • 1. Participant has been receiving invasive mechanical ventilation for \> 96 hours.
- • 2. Participant is scheduled or expected to be disconnected from mechanical ventilation ≤ 24 hours after enrollment.
- • 3. Participant was intubated for ≥ 24 hours during a prior episode of invasive mechanical ventilation during current hospitalization.
- • 4. Participant has a BMI ≥ 40 Kg/m2.
- • 5. Participant has no contraction of the abdominal wall muscles in response to abdominal FES as determined by ultrasound.
- • 6. Participant has a pre-existing neuromuscular or muscular disorder that could affect the respiratory muscles (e.g., spinal cord injury or Guillain-Barré syndrome).
- • 7. Participant has had open abdominal surgery ≤ 4 weeks prior to enrollment.
- • 8. Participant has open or damaged skin at area of electrode placements.
- • 9. Participant has a pacemaker and/or implanted electronic device.
- • 10. Participant is known or expected to be pregnant. NOTE: A negative urine or blood pregnancy test will be documented during screening for women of child-bearing potential.
- • 11. Participant is actively pharmacologically paralyzed at the time of enrollment. NOTE: Participants receiving neuromuscular blockers may be enrolled after a ≥ 12-hour washout period.
- • 12. Participant is tracheostomized at the time of enrollment.
- • 13. Participant is on home non-invasive ventilation (except for CPAP or BiPAP for obstructive sleep apnea).
- • 14. Participant is receiving or expected to receive comfort measures (palliative, hospice, comfort care, etc.) at the time of screening or enrollment.
- 15. Participant is participating in any of the following:
- • A study with the same or similar primary endpoint
- • A study investigating electrical stimulation or respiratory muscle therapy
- • Any study in which the investigator determines may interfere with the results of this study
- • 16. Participant is unable or unwilling to comply with protocol requirements, including assessments, tests, and follow-up visits.
- • 17. Participant has any other medical condition which in the opinion of the Investigator will make participation medically unsafe or interfere with the study results.
- • 18. Participant or legally authorized representative is unwilling to provide written informed consent.
- • 19. Participant or legally authorized representative is unable to provide written informed consent.
About Liberate Medical
Liberate Medical is an innovative clinical trial sponsor dedicated to advancing healthcare solutions through cutting-edge research and development. Focused on improving patient outcomes, the company specializes in the design and execution of clinical trials aimed at evaluating novel medical technologies and therapies. With a commitment to ethical practices and regulatory compliance, Liberate Medical collaborates with healthcare providers, researchers, and regulatory bodies to ensure the rigor and integrity of its studies. By leveraging data-driven insights and patient-centered approaches, Liberate Medical strives to bring transformative medical advancements to market, ultimately enhancing the quality of care for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Houston, Texas, United States
Iowa City, Iowa, United States
Pittsburgh, Pennsylvania, United States
Cincinnati, Ohio, United States
Houston, Texas, United States
Boston, Massachusetts, United States
Nashville, Tennessee, United States
Cincinnati, Ohio, United States
Maywood, Illinois, United States
Rotterdam, , Netherlands
Hines, Illinois, United States
Nijmegen, , Netherlands
Houston, Texas, United States
Clayton, , Australia
Everett, Washington, United States
Randwick, , Australia
Kogarah, , Australia
St. Leonards, , Australia
Kingswood, , Australia
Houston, Texas, United States
Paris, , France
'S Hertogenbosch, , Netherlands
Nijmegen, , Netherlands
Patients applied
Trial Officials
Angus Mclachlan, PhD
Study Director
Liberate Medical
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials